CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
CorMedix (NASDAQ:CRMD) Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving from what he described as a “single product company” to a diversified specialty pharmaceutical business focused on institutional settings of care following its 2025 acquisition of Melinta. Todisco said CorMedix is now centered on largely injectable therapies used in hospitals and clinics, with a portfolio that is “largely anti-infective” today. Rather than focusing on a single therapeutic area, he said the company aims to leverage its commercial infrastructure across multiple specialties that share similar sites of care, including hospitals and infusion clinics. DefenCath adoption and the TDAPA transition ? Broadcom's AI Momentum Could Be Far From Over Why CorMedix Could be the Biopharma Name to Watch Early in 2026 Todisco highlighted DefenCath, an antimicrobial catheter lock so
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its price target lowered by Needham & Company LLC from $15.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- CorMedix Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 3/6/26 - Form 8-K
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- CRMD's page on the SEC website